

4 March 2026

ASX Announcement

CRADA with USAMRIID and the Geneva Foundation to accelerate Galidesivir Animal Rule Approval

- **Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Geneva Foundation**
- **USAMRIID is the US Army's premier research institute and Biosafety Level-facility for the study of naturally occurring infectious diseases and medical countermeasures against biowarfare threat agents**
- **Geneva Foundation is a non-profit that accelerates operationally relevant, military-unique research aligning with US Department of War (DoW) requirements**
- **USAMRIID has played a central role in Galidesivir's historical development, including preclinical and non-human primate studies**
- **Previous studies highlight exceptional survival rates in Marburg and Ebola infected non-human primates following Galidesivir administration**
- **CRADA provides exceptional optionality to accelerate Galidesivir's Animal Rule development pathway against Marburg Virus Disease (MVD)**

MELBOURNE Australia, 4 March 2026: Antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID or the Institute), a part of the Defense Health Agency (DHA), and The Geneva Foundation for Medical Research (Geneva) to advance Galidesivir under the US Food & Drug Administration's (FDA) Animal Rule development pathway for the treatment of Marburg Virus Disease (MVD).

About the US Army Medical Research Institute of Infectious Diseases:

For over 50 years, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of War (DoW) equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to medical solutions – vaccines, drugs, diagnostics, information, and training programs – that benefit both military personnel and civilians. Established in 1969, the Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the US Army Medical Research and Development Command. For more information, visit <https://usamriid.health.mil/>.

USAMRIID has been instrumental in Galidesivir's historical development, supporting preclinical through to non-human primate studies demonstrating potent antiviral activity against Ebola and Marburg (refer ASX announcement: 17 September 2025).

About The Geneva Foundation:

Geneva is a leading US-based, non-profit organisation advancing military medical research that protects force health and national security. Established in 1993, Geneva partners with the DoW, federal agencies, academia, and industry to accelerate the development of critical medical countermeasures and operational solutions for high-consequence health threats.

Geneva manages approximately US\$383 million in annual research funding and maintains active collaborations with 49 universities and academic medical centres and 95 industry partners, supporting programs across 39 DoW installations. Geneva brings deep expertise in government-sponsored biodefence programs, regulatory navigation, research operations, and compliant program execution, positioning the organisation as a highly credible and strategically aligned collaborator for Galidesivir's advancement.

As part of the CRADA, Island, USAMRIID, and Geneva will collaborate to design and conduct non-human primate (NHP) studies required to progress Galidesivir toward new drug application (NDA) approval for use in MVD under the FDA's Animal Efficacy Rule (refer ASX announcement: 4 February 2026). The term of the agreement is three years and this three-party CRADA includes optionality to expand this collaboration as needed to continue to accelerate the development of Galidesivir for the treatment of MVD.

The information contained in this press release does not necessarily reflect the position or the policy of the US Government and no official endorsement should be inferred.

Management commentary:

CEO and Managing Director, Dr David Foster said: *"This CRADA is a strategically important milestone and further validates Galidesivir's position within the U.S. biodefence ecosystem. Formal collaboration with USAMRIID – the Department of War's leading high-containment medical research institute for infectious diseases – and The Geneva Foundation – a leading government program accelerator – significantly strengthens our ability to efficiently execute the final stages of the Animal Rule development pathway."*

"Galidesivir has a long-standing history with USAMRIID, including successful non-human primate studies in Ebola and Marburg. This agreement builds on that foundation and directly supports the data generation required for potential approval in Marburg."

"Importantly, this collaboration further aligns Island with US Government biodefence priorities could operate as both a clinical and commercial accelerator as we advance toward Animal Rule approval."

- Ends -

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:
Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.